Adipotide

Using phage-display screening, the authors identified a cyclic nonapeptide (CKGGRAKDC) that homes selectively to the vasculature of white adipose tissue, where it binds prohibitin on the luminal endothelial surface. Conjugating this homing motif to a pro-apoptotic peptide (the KLAKLAK dimer) produced a chimeric agent (the prototype of adipotide) that ablated adipose vasculature via targeted endothelial apoptosis. In ob/ob and diet-induced obese mice, systemic administration caused resorption of white fat and rapid reversal of obesity, reported without detectable adverse effects at the tested doses.

Scientists found a tiny peptide that acts like a zip code, homing only to the blood vessels that feed white fat. They attached a self-destruct signal to it so it would kill those vessels, starving the fat tissue. In obese mice the fat shrank and the animals lost weight quickly, which was the first proof of concept for adipotide.

Spontaneously obese rhesus monkeys given daily subcutaneous adipotide for 28 days lost roughly 11 percent of body weight, with reductions in abdominal adiposity confirmed by MRI and PET imaging, plus improved insulin sensitivity independent of the weight loss. The effect was dose-dependent and largely reversible after treatment stopped. Importantly, the study documented renal toxicity: dose-related, monitorable changes in kidney function and histology were observed, flagging the nephrotoxicity signal that has constrained clinical translation.

In naturally obese monkeys, a month of daily injections produced about 11 percent weight loss, targeted belly fat, and better blood-sugar control. The fat came back after treatment stopped, showing the effect was not permanent. The study also honestly reported kidney damage tied to the dose, which is the main safety concern that has held the drug back from people.

This mechanistic study characterized the molecular target that adipotide exploits, showing that prohibitin on adipose endothelium partners with annexin A2 to regulate CD36-mediated long-chain fatty acid transport into white fat. Disrupting the prohibitin/annexin 2 interaction impaired fatty acid uptake, clarifying why prohibitin is enriched on and functionally important to fat vasculature. The work grounds the rationale for prohibitin-directed anti-obesity strategies in defined receptor biology.

This paper explains the biology behind adipotide's target. It shows that prohibitin, the protein adipotide latches onto, teams up with another protein to help move fat-building fuel into fat tissue. Blocking that partnership cut off the fat supply, confirming why prohibitin is a sensible bullseye for fat-targeting drugs.